Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 8/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | APLNR | P35414 | 5/20 | 0.41 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861082 | 0.76 | PTGS2 (0.51) | SLC6A4SLC6A2SLC6A3CHRM1 | |
| SCHEMBL10148196 | 0.74 | SLC6A4 (0.43) | SLC6A4SLC6A2SLC6A3CHRM1APLNR | |
| SCHEMBL13287108 | 0.73 | PTGS2 (0.51) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL878698 | 0.73 | ALB (0.47) | AVPR2 | |
| SCHEMBL860893 | 0.71 | CA12 (0.48) | SLC6A4SLC6A2SLC6A3CHRM1AVPR2 | |
| SCHEMBL878167 | 0.69 | HDAC3 (0.32) | — | |
| SCHEMBL878681 | 0.69 | MEN1 (0.68) | SLC6A4SLC6A2SLC6A3CHRM1APLNR | |
| SCHEMBL861715 | 0.69 | PTGS2 (0.51) | — | |
| SCHEMBL16181479 | 0.68 | PTGS2 (0.51) | — | |
| SCHEMBL12415015 | 0.68 | MEN1 (0.57) | SLC6A4SLC6A2SLC6A3CHRM1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143302-B2 | Methods and compositions for diagnostic and therapeutic targeting of COX-2 | VANDERBILT UNIVERSITY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | VANDERBILT UNIVERSITY (US) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254910-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 | PTGS2, PTGES2, PTGER2 | SLC6A4 3021/4885SLC6A2 2161/4885SLC6A3 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.